Skip to main content

NKTR

Stock
Health Care
Biotechnology

Performance overview

NKTR Price
Price Chart

Forward-looking statistics

Beta
1.65
Risk
88.81%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees478
Market cap$231.9M

Fundamentals

Enterprise value$288.6M
Revenue$87.2M
Revenue per employee—
Profit margin-152.49%
Debt to equity1358.71

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$9.45
Dividend per share—
Revenue per share$6.24
Avg trading volume (30 day)$74M
Avg trading volume (10 day)$206M
Put-call ratio—

Macro factor sensitivity

Growth-2.7
Credit+7.4
Liquidity+1.8
Inflation-6.2
Commodities-1.8
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio-32.16
Price to sales3.52
P/E Ratio-32.16
Enterprise Value to Revenue3.31
Price to book22.37

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend dayJune 11, 2014

News

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Nektar Therapeutics NKTR released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.

Benzinga (June 25, 2025)
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

Zacks Investment Research (June 25, 2025)
Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today's trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for treating moderate-to-severe atopic dermatitis (eczema), marking a pivotal moment for the cash-strapped biotech company. The study met both primary and secondary endpoints, validating the company's novel regulatory T-cell approach to treating inflammatory skin conditions.

Forbes (June 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free